leadf
logo-loader
viewAvacta Group PLC

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half.

Stacey says alongside the recent release of their interim results, Avacta's announced a proposed equity placing of up to £9mln.

The biggest deployment of the new funds will be the AVA6000 pro-doxorubicin tumour-targeted chemotherapy programme developed via the Tufts collaboration.

Quick facts: Avacta Group PLC

Price: 139.7 GBX

AIM:AVCT
Market: AIM
Market Cap: £353.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Crossword Cybersecurity 'delighted' with 25% revenue growth despite...

Crossword Cybersecurity PLC's (LON:CCS) Mary Dowd talks to Proactive London about their 25% revenue growth growth plan. In a trading update for the year to December 31, 2020, the company said overall revenues are expected to show an increase of 25% to £1.6mln. Dowd goes on to explain the...

1 hour, 3 minutes ago

2 min read